MapLight Therapeutics, Inc.
NASDAQMPLT short interest drops 27.9% over the past week to 7.2% of float, as availability surges to 98.5% from a 52-week low of 1.1%.
MPLT enters its August 14 print carrying the scars of a dramatic analyst reset — and the question heading into Thursday is whether the ZEPHYR Phase 2b data can reopen the bull case that was closed so abruptly two weeks…
MPLT heads into today's earnings release with the most bullish analyst consensus it has carried since going public. The analyst setup is unusually clean for a clinical-stage biotech. Every firm covering the stock…
Snapshot as of 2 Sept 2026
MapLight Therapeutics heads into its June 4 earnings report with a wave of fresh analyst conviction — and a stock that has moved sharply in the wrong direction. The analyst story is unusually clean for a clinical-stage…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for MPLT — free to start on ORTEX.
Sign up for free →Open MPLT on ORTEX